<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Carcinoembryonic antigen (CEA, CEACAM5, and CD66e) has been found to be associated with various types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, particularly colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp>, and developed to be a molecular target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis and therapy </plain></SENT>
<SENT sid="1" pm="."><plain>In present study, we generated a novel anti-CEACAM5 monoclonal antibody, namely mAb CC4, by immunizing mice with living <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> LS174T cells </plain></SENT>
<SENT sid="2" pm="."><plain>Immunohistochemical studies found that mAb CC4 specifically and strongly binds to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues, especially colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In xenografted mice, mAb CC4 is specifically accumulated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site and remarkably represses <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> growth </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro functional analysis showed that mAb CC4 significantly suppresses cell proliferation, migration and aggregation of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells and also raises strong ADCC reaction </plain></SENT>
<SENT sid="5" pm="."><plain>More interestingly, mAb CC4 is able to enhance NK cytotoxicity against MHC-I-deficient <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells by blocking intercellular interaction between epithelial CEACAM5 and NK inhibitory receptor CEACAM1 </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest that mAb CC4 has the potential to be developed as a novel <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-targeting carrier and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapeutic </plain></SENT>
</text></document>